X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Dwindling margins - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Aug 11, 2003

    Novartis: Dwindling margins

    MNC pharma major, Novartis announced its 1QFY04 results recently. While the company has recorded a marginal growth in topline, the operating profits have seen a 25% drop. However, sharp rise in other income and lower tax provisions have helped Novartis register a 6% growth in the bottomline. In this context, let us briefly evaluate the performance of the company.

    (Rs m) 1QFY03 1QFY04 % change
    Sales 1,275 1,328 4.1%
    Other Income 40 81 101.7%
    Expenditure 1,032 1,144 10.9%
    Operating Profit (EBDIT) 244 184 -24.6%
    Operating Profit Margin (%) 19.1% 13.8%  
    Interest 2 2 -4.5%
    Depreciation 21 38 81.0%
    Profit before Tax 261 225 -13.7%
    Tax 94 48 -48.5%
    Profit after Tax/(Loss) 167 176 5.9%
    Net profit margin (%) 13.1% 13.3%  
    No. of Shares (eoy) (m) 31.7 31.7  
    Diluted Earnings per share* 21.0 22.3  
    P/E (at current price) 11.0  

    Novartis derives a major portion of its revenues from the pharma business. This segment saw a 6.6% YoY growth to Rs 810 m. The company’s strategy of revitalizing its mature product portfolio by introducing product extensions and variants seems to be paying off. New line extensions of a nasal decongestant and a Calcium Sandoz variant were key to the 19.7% growth in the OTC sales to Rs 134 m. Pricing pressure and a decline in the anti-TB business resulted in Novartis recording an 18.4% decline in the generics business to Rs 248 m.

    Expenditure as a % of sales
    (Rs m) 1QFY03 1QFY04
    Purchase of materials & finished goods 50.1% 54.2%
    Staff cost 8.8% 9.4%
    Others 22.0% 22.6%

    Despite an increase in net sales, a rise in the materials cost from 50% of revenues to 54% of revenues has resulted in Novartis recording a steep 25% decline in the operating profits. The company has incurred VRS expenditure of Rs 9 m during the current quarter. However, a sharp rise in the other income coupled with a drop in the tax provisions has enabled the company record a marginal increase in net profit. Other income has increased on account of a reversal of provision for wealth tax of Rs 21 m (1QFY03 – Nil) and interest from tax authorities of Rs 18 m (1QFY03 – Nil). Tax provisions, on the other hand, have declined due to a write back of provisions for earlier years of Rs 23 m (1QFY03 – Rs 8 m).

    At Rs 245, Novartis is trading at a P/E of 11x its 1QFY04 earnings. Novartis has received shareholder’s approval for the buyback of shares upto an amount not exceeding 25% of its paid up share capital and free reserves at a price not exceeding Rs 250 per share. The company has been witnessing intense pricing pressure and declining margins in the recent times. Further, with the implementation of the new DPCO order, a major portion of its product portfolio is expected to come under DPCO cover. This could put additional pressure on the margins of the company going forward. Hence, the prospects of the company in the medium-term remain a cause of concern.

     

     

    Equitymaster requests your view! Post a comment on "Novartis: Dwindling margins". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    NOVARTIS SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK NOVARTIS

    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    NOVARTIS - ALKEM LABORATORIES COMPARISON

    Compare Company With Charts

    COMPARE NOVARTIS WITH

    MARKET STATS